Test Your Knowledge of eNSCLC Research Presented at ESMO!
Do you remember the eNSCLC research presented at ESMO? Test your knowledge now!
Dec 6, 2023
MEETING BRIEF
ESMO 2023: eNSCLC
The latest news from ESMO 2023 on early non-small cell lung cancer (eNSCLC), including abstracts, featured articles, and information about the conference.
Curated ESMO 2023: eNSCLC eBook
Curated ESMO 2023: eNSCLC eBook
A curated eBook featuring ESMO 2023: eNSCLC-focused studies, findings, and expert opinions.
The Importance of Detecting Early NSCLC
The Importance of Detecting Early NSCLC
Disease-free survival could be predicted by high expression of TGFβ CAF in patients with eNSCLC treated with atezolizumab.
Advertisement
PW QUIZ
Advertisement
Can Radiotracers Predict Response to PD-L1 Inhibitors in Early NSCLC?
Can Radiotracers Predict Response to PD-L1 Inhibitors in Early NSCLC?
Although immunotherapy advances have improved cancer treatments, there remains a need for reliable biomarkers.
Q&A: Using Effective Treatments Earlier for NSCLC
Q&A: Using Effective Treatments Earlier for NSCLC
“With lung cancer we’re treating more patients effectively today and even curing them because we're using our most effective therapies earlier.”
EXPLORE MORE
Q&A: Availability of Multiple Options for NSCLC is “Very Exciting”
Selecting a treatment for operable non-small cell lung cancer from the many options available involves consideration of tumor stage and biomarkers.
AI Demonstrates Ability to Predict Survival of Patients Receiving Immunotherapy
For a retrospective study involving 607 oncology patients treated from 2014-2019, the potential for predicting patient prognosis and guiding immunotherapy treatment through the analysis of total tumor volume (TTV) and artificial intelligence (AI) tumor heterogeneity from CT scans was investigated.
Stay connected to the latest news with Physician’s Weekly
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.
